Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Safety: Treatment-emergent adverse events (TEAEs) Measure: Change in disease activity biomarkers. After: Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Measure: Maximum Change From Baseline in Hemoglobin Levels Measure: Change From Baseline in Lactate Dehydrogenase Levels at Day 71 Measure: Change From Baseline in Percentage of Reticulocytes/Total Cells Count at Day 71 Measure: Change From Baseline in Haptoglobin Levels at Day 71 Measure: Change From Baseline in Total Bilirubin Levels at Day 71 Measure: Change From Baseline in Indirect Bilirubin Levels at Day 71.
Actual enrollment increased by 1 participants
Before: 6 participants (actual). After: 7 participants (actual).